GlaxoSmithKline aims to boost its financial performance with electroceuticals

By Jonathan Dyble
With GlaxoSmithKline (GSK) under pressure due to its development line having failed to produce anything of significance of late, the company is putting...

With GlaxoSmithKline (GSK) under pressure due to its development line having failed to produce anything of significance of late, the company is putting faith into the creation of electroceuticals.

In a nutshell, electroceuticals are tiny specialised electronic implants that have the capabilities of treating a variety of diseases including diabetes, asthma, arthritis, hypertension amongst others.

Through its subsidiary company Galvani Bioelectronics, a joint venture with Google’s parent company Alphabet, GSK is looking to become the first firm to effectively manufacture such a device.

See Also:

“Maybe over the next 12 months we’ll have one [a device],” said Kris Famm, the man running the 45 strong team behind the venture, in an interview with The Guardian.

“This is a decade-long endeavour. From the mid-2020s we should see a wave of therapies that will make this [bioelectronics] much more commonplace.”

The emphasis on electroceuticals comes at a time when GSK’s new Chief Executive Emma Walmsley has scrapped nearly one in seven of the company’s development programmes in order to streamline and focus on potentially blockbuster products.

It is understood that the company will remain committed to its development, providing £540mn of funding over the next seven years alongside Alphabet’s Verily division.

Share

Featured Articles

Healthcare Business roundup: Baxter, Sanofi & Eli Lilly

Baxter International to sell kidney care spin-off Vantive; Sanofi's consumer health unit ‘to be separated’; Eli Lilly to buy Morphic Holding for $3.2bn

Trane Technologies Helping US Hospitals Meet Climate Pledge

Christy Fetsch of Trane Technologies explains how the company is helping US hospitals meet White House sustainability pledges for US healthcare provision

Nestlé Health Science Targets Weight Loss Side-Effects

Nestlé Health Science launches nutrition initiative to counteract side effects of weight-loss drugs, including hollowed-out 'Ozempic Face'

Eli Lilly Alzheimer's Drug Kisunla Approved in US by FDA

Medical Devices & Pharma

WEF: Gender Health Gap 'Costs women 75mn years of Life'

Medical Devices & Pharma

Schneider: Swathe of NHS Failing to Measure Sustainability

Sustainability